Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
Nicholas J. Ashton(King's College London), Henrik Zetterberg(University of Wisconsin–Madison), Anniina Snellman(Turku University Hospital), Kaj Blennow(Sahlgrenska University Hospital), Juan Lantero‐Rodriguez(University of Gothenburg), Mathias Sauer(Sahlgrenska University Hospital), Thomas K. Karikari(University of Pittsburgh), Marc Suárez‐Calvet(Pasqual Maragall Foundation), Karine Fauria(Pasqual Maragall Foundation), Carolina Minguillón(Pasqual Maragall Foundation), Joel Simrén(University of Gothenburg)
Cited by 128
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k